Loading clinical trials...

COMPLETED

Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy

A Retrospective Multicenter Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy

NCT03208660•Eisai Inc.

View on ClinicalTrials.gov

Summary

This study is conducted to assess the retention rate of Fycompa when given in routine clinical care.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Participants must have met all of the following criteria to be included in this study:
•1. Diagnosis of epilepsy
•2. Initiated treatment with Fycompa at any time after 01 Jan 2014
•3. Provided written informed consent by the participant or the participant's legally authorized representative signed for the use of medical records (if required by an Institutional Review Board \[IRB\] or Independent Ethics Committee \[IEC\], or by regulatory authorities).

Exclusion Criteria

•Not applicable

Locations (44)

Arizona Age Reversal & Neurology Clinic

Phoenix, Arizona, United States

Bronislava Shafran, MD, PC

Phoenix, Arizona, United States

Banner - University Medical Center Phoenix

Phoenix, Arizona, United States

Arizona Neurological Institute

Sun City, Arizona, United States

The University of Arizona Department of Neurology

Tucson, Arizona, United States

Valley Children's Hospital

Madera, California, United States

UC Davis Medical Center

Sacramento, California, United States

Sutter Health

Sacramento, California, United States

Colorado Springs Neurological Associates

Colorado Springs, Colorado, United States

Boca Raton Regional Hospital

Boca Raton, Florida, United States

Key Dates

Start Date

April 7, 2017

Primary Completion Date

March 15, 2019

Completion Date

March 15, 2019

Last Updated

April 11, 2019

Enrollment

2,000

ACTUAL participants

Conditions

Epilepsy

Interventions

Fycompa

DRUG

Thalamus Seizure Detection With a Deep Brain Stimulator System

NCT06700356

Epilepsy; Seizure

View study

RECRUITINGPHASE1

Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy

NCT02531880

Epilepsy

View study

RECRUITINGNA

Intracranial Investigation of Neural Circuity Underlying Human Mood

NCT05871372

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 11, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy

Inclusion Criteria

Exclusion Criteria

Thalamus Seizure Detection With a Deep Brain Stimulator System

Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy

Intracranial Investigation of Neural Circuity Underlying Human Mood

Late-Onset Seizures: Trial of Vascular Risk Investigation and Treatment

AI-Based Mobile Intervention on Medication Non-Adherence and Transition

MEHMO Natural History and Biomarkers